Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Nuscale Power Corporation (SMR) Price & Performance

ARK Genomic Revolution ETFTrade
Nuscale Power CorporationTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Nuscale Power Corporation — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while Nuscale Power Corporation trades at $9.64 (market cap $4.06B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.

ARKGSMR
Sector
Sector/ThematicUtilities
52-Week High
$44.55$53.43
52-Week Low
$24.02$7.59
Market Cap
$4.06B
Enterprise Value
$2.99B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.

Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.

Nuscale Power Corporation

NuScale Power (SMR) trades at $9.76, up 6.32% in the last session, with a bullish technical signal from moving averages. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with negative margins, while analyst consensus is a Buy with a $10.50 price target. Recent news highlights regulatory progress and AI-driven power demand as growth catalysts.

Outlook hinges on commercial deployment of small modular reactors, offering high upside if execution succeeds, but risks include persistent losses, revenue volatility, and project delays. The stock presents speculative growth potential amid significant operational and financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Nuscale Power Corporation

NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.

Read more on SMR